Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization

Documenti analoghi

• Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies
  di: Amanda E. Marinoff, et al.
  Pubblicazione: (2025)
• Hyperinsulinism‐induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)‐rywn chemotherapy in a pediatric AML patient
  di: Ashley Carlo, et al.
  Pubblicazione: (2024)
• Desensitization with daratumumab in a pediatric patient with thalassemia major and high donor‐specific antibody prior to haploidentical transplantation
  di: Nuttra Suwantarat, et al.
  Pubblicazione: (2024)
• Parenteral iron therapy in children with iron deficiency anemia: A single‐institution experience
  di: Jelena Roganovic
  Pubblicazione: (2024)
• Azacytidine Monotherapy in an Infant With Mosaic NRAS ‐Driven Juvenile Myelomonocytic Leukemia
  di: Jeremy M. Grenier, et al.
  Pubblicazione: (2025)